These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Kratz CP; Niemeyer CM; Castleberry RP; Cetin M; Bergsträsser E; Emanuel PD; Hasle H; Kardos G; Klein C; Kojima S; Stary J; Trebo M; Zecca M; Gelb BD; Tartaglia M; Loh ML Blood; 2005 Sep; 106(6):2183-5. PubMed ID: 15928039 [TBL] [Abstract][Full Text] [Related]
8. Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review. Hoshino Y; Moriya K; Mitsui-Sekinaka K; Hashimoto Y; Nakayama S; Sajiki D; Muramatsu H; Hagiwara H; Suzuki S; Sekinaka Y; Wakamatsu H; Kawaguchi H; Imai K J Pediatr Hematol Oncol; 2024 Mar; 46(2):e176-e179. PubMed ID: 38132703 [TBL] [Abstract][Full Text] [Related]
9. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593 [TBL] [Abstract][Full Text] [Related]
10. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418 [TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639 [TBL] [Abstract][Full Text] [Related]
12. Transient Myeloproliferative Disorder (TMD), Acute Lymphoblastic Leukemia (ALL), and Juvenile Myelomonocytic Leukemia (JMML) in a Child with Noonan Syndrome: Sequential Occurrence, Single Center Experience, and Review of the Literature. Arrabito M; Li Volsi N; La Rosa M; Samperi P; Pulvirenti G; Cannata E; Russo G; Di Cataldo A; Lo Nigro L Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336782 [TBL] [Abstract][Full Text] [Related]
13. Use of human androgen receptor gene analysis to aid the diagnosis of JMML in female noonan syndrome patients. Lavin VA; Hamid R; Patterson J; Alford C; Ho R; Yang E Pediatr Blood Cancer; 2008 Aug; 51(2):298-302. PubMed ID: 18454468 [TBL] [Abstract][Full Text] [Related]
14. K-RasV14I recapitulates Noonan syndrome in mice. Hernández-Porras I; Fabbiano S; Schuhmacher AJ; Aicher A; Cañamero M; Cámara JA; Cussó L; Desco M; Heeschen C; Mulero F; Bustelo XR; Guerra C; Barbacid M Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16395-400. PubMed ID: 25359213 [TBL] [Abstract][Full Text] [Related]
15. Reduction of CFU-GM and circulating hematopoietic progenitors in a subgroup of children with chronic neutropenia associated with severe infections and delayed recovery. Timeus F; Crescenzio N; Foglia L; Doria A; Stillitano MG; Garelli E; Mazzone R; Vivalda L; Vallero S; Ramenghi U; Saracco P PLoS One; 2019; 14(3):e0213782. PubMed ID: 30870474 [TBL] [Abstract][Full Text] [Related]
16. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
17. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411 [TBL] [Abstract][Full Text] [Related]
18. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay. Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384 [TBL] [Abstract][Full Text] [Related]
19. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234 [TBL] [Abstract][Full Text] [Related]
20. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia. Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]